Systematic Review and Meta-Analysis Comparing the Safety of Natalizumab, Ocrelizumab, and Alemtuzumab in Treating Relapsing–Remitting, Primary Progressive, and Secondary Progressive Multiple Sclerosis | IMSEAR

Main content 1 Search 2 Footer 3

+A A -A High contrast

Systematic Review and Meta-Analysis Comparing the Safety of Natalizumab, Ocrelizumab, and Alemtuzumab in Treating Relapsing–Remitting, Primary Progressive, and Secondary Progressive Multiple Sclerosis

Raina, P; Basu, S; Goyal, RK; Sahoo, PK; Mathur, R..

Article | IMSEAR | ID: sea-216043

Key words

Adverse event; Multiple sclerosis; Monoclonal antibody; Safety

Search on Google

Full text: 1 Index: IMSEAR Type of study: Systematic_reviews Year: 2022 Type: Article

Search on Google

Full text: 1 Index: IMSEAR Type of study: Systematic_reviews Year: 2022 Type: Article